Physician profile
April Enard
NPI 1558654087
$1,361.14
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $86.10 · 2022: $793 · 2023: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $345.14 | 2020-2022 | |
| Lilly USA, LLC | $138.23 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $132.17 | 2020-2023 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $131.69 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.02 | 2022 | |
| Pfizer INC. | $59.02 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $53.41 | 2019 | |
| Glaxosmithkline, LLC. | $51.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $42.04 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.85 | 2022 | |
| Impel Pharmaceuticals INC. | $38.11 | 2023 | Trudhesa |
| Abbvie INC. | $31.60 | 2022-2023 | |
| Daiichi Sankyo INC. | $28.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.34 | 2022 | |
| Abbott Laboratories | $22.64 | 2023 | Freestyle Libre 2 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.21 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.44 | 2022 | |
| Amarin Pharma, INC. | $18.18 | 2022 | |
| Seqirus USA INC | $17.63 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $16.54 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $16.03 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.43 | 2023 | Livalo, Seglentis |
| Tris Pharma INC | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Enard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.